Parkinsons is a brain disorder that causes shaking, difficulty in balance, and coordination. The market is expected to grow, owing to the increasing cases of Parkinsons disease, with rising aging population. Pharmaceutical firms are developing new and improved therapies for Parkinsons disease, which is driving the growth of the market.
MARKET DYNAMICS
The Parkinsons disease drug market is driving due to the geriatric population and burden of Parkinsons disease, and expected launch of many blockbuster drugs during the forecast period. However, high cost of treatment is expected to hamper the growth of the global Parkinsons disease Drug market. Moreover, recent product launches and the high number of therapeutics in product pipelines is anticipated to drive demand the growth of the market.
MARKET SCOPE
The "Parkinsons Disease Drug Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of Parkinsons disease Drug market with detailed market segmentation by mechanism of action. The Parkinsons disease drug market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Parkinsons disease Drug market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The Parkinsons disease drug market is segmented based on mechanism of action. Based on mechanism of action, the market is segmented into plastic dopamine agonists, anticholinergic, MAO-B inhibitors, amantadine, carbidopa-levodopa, COMT inhibitors, and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Parkinsons disease Drug market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Parkinsons disease drug market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Parkinsons disease drug market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely, North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social, and technological factors effecting the Parkinsons disease drug market in these regions.
MARKET PLAYERS
The report covers key developments in the Parkinsons disease drug market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Parkinsons disease drug market are anticipated to have lucrative growth opportunities in the future with the rising demand for Parkinsons disease drug market in the global market. Below mentioned is the list of few companies engaged in the Parkinsons disease drug market.
The report also includes the profiles of key players in Parkinsons disease drug market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Merck & Co. Inc.
- Pfizer Inc.
- Impax Laboratories Inc.
- AbbVie Inc.
- Mylan NV
- Novartis AG
- Boehringer Ingelheim GmbH
- Teva Pharmaceuticals Industries Ltd
- GlaxoSmithKline PLC
- M Somerset Pharmaceuticals Inc.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.